Millions of Americans have atrial fibrillation, or AFib, the most common type of heart arrhythmia.1 It is estimated that by 2030 AFib will affect 12.1 million people in the United States.2 When AFib is allowed to progress over time, episodes may occur more frequently or last longer and potentially lead to serious life-threatening complications.3 At Sanofi, we are combining our vast experience and trusted brands with the power of technology and digital innovation to develop simplified, tailored care solutions that will help the management of cardiovascular conditions including AFib.
Cardiovascular facts
- Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States1.
- More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year in the United States2.
- AFib contributes to about 158,000 deaths each year3.
- It is estimated that 12.1 million people in the United States will have AFib in 20303.
References:
- Centers for Disease Control and Prevention. Heart Disease Facts. Available at: https://www.cdc.gov/heartdisease/facts.htm
- Centers for Disease Control and Prevention. What is atrial fibrillation? Available at: https://www.cdc.gov/heartdisease/atrial_fibrillation.htm
- Centers for Disease Control and Prevention. What are the consequences of AFib? Available at: https://www.cdc.gov/heartdisease/atrial_fibrillation.htm
MAT-US-2400663-v1.0-02/2024